Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs TransMedics Group Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.54, while TransMedics Group Inc trades at $87.24 (market cap $3.10B). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| KOLD | TMDX | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $49.39 | $150.42 |
52-Week Low | $13.58 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD, an inverse ETF tracking natural gas futures, trades at $28.34, down 1.05% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. Recent news highlights natural gas price volatility driven by weather forecasts and LNG export fluctuations, with the ETF positioned as a tactical tool for traders amid market swings.
The outlook for KOLD hinges on continued natural gas price volatility, offering short-term trading opportunities but carrying high risk due to its leveraged structure. Key risks include rapid price reversals in natural gas and macroeconomic shifts affecting energy demand, requiring careful risk management for investors.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
